BioSpace News Archive

DaVita Inc., announced preliminary second quarter 2019 financial and operating results and updated guidance for fiscal year 2019.

Axonics Modulation Technologies, Inc. announced that it will release financial results for the second quarter and first six months of 2019, and provide an update on operations and FDA regulatory status after the market closes on Monday, August 5, 2019.

DAVITA INC. announced that it has commenced a modified “Dutch auction” tender offer for up to $1.2 billion of its common stock at a price per share not less than $53.50 and not greater than $61.50.

CalTree™ software to be important piece of company-wide calibration automation platform expected to drive greater Service segment efficiencies and enhanced margins

Epizyme, Inc., a late-stage biopharmaceutical company developing novel epigenetic therapies, announced the appointment of Paolo Tombesi as chief financial officer, effective August 2019.

Compugen Ltd. announced that the Company will release its second quarter 2019 financial results on Monday, August 5, 2019 before the U.S. financial markets open.

Intec Pharma Ltd. announces top-line data from the Company’s pivotal Phase 3 trial evaluating the safety and efficacy of the Accordion Pill®-Carbidopa/Levodopa compared with immediate release CD/LD as a treatment for the symptoms of advanced Parkinson’s disease.

The funding company reports the manufacturing giant is under fire for distributing faulty Essure birth control implants.

Vanda Pharmaceuticals Inc. announced that on July 19, 2019, it received a notification from the U.S. Food and Drug Administration stating that as part of its ongoing review of Vanda’s supplemental New Drug Application for HETLIOZ® for the treatment of Jet Lag Disorder, the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, announced completion of enrollment in its Phase 2a study of RSLV-132 for the treatment of Systemic Lupus Erythematosus (SLE; “lupus”).